Navigation Links
Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN)
Date:5/17/2012

RARITAN, N.J., May 17, 2012 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. today announced the results of an investigational Phase 3 study suggesting NUCYNTA® ER (tapentadol) extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neuropathy (DPN). Results of the study were presented at the 31st Annual Scientific Meeting of the American Pain Society being held May 16-19 in Honolulu, Hawaii.

Diabetes affects nearly 26 million people in the United States(1)– and its prevalence is expected to grow significantly during the coming decades(2). Over time, people with diabetes can develop a type of nerve damage called neuropathy. Approximately 60 to 70 percent of people with diabetes have some form of neuropathy(3). The most common type is diabetic peripheral neuropathy, which causes pain or loss of feeling in the toes, feet, legs, hands, and arms.

The study found, among patients who had at least a one-point reduction in pain intensity during three weeks of treatment with tapentadol ER, those who continued on an optimized dose of tapentadol ER (100-250 mg twice daily) for an additional 12 weeks experienced significantly better pain control compared to those who switched to placebo(4). Treatment-emergent adverse events reported in 10 percent or more of tapentadol ER-treated patients during the double-blind maintenance period included nausea (21.1 percent) and vomiting (12.7 percent)(4).

"Painful DPN is a common and burdensome complication of diabetes, and controlling pain in people with DPN can be challenging," said Aaron I. Vinik, M.D., Ph.D., FCP, MACP, Director of Research and Neuroendocrine Unit at Strelitz Diabetes Center for Endocrine and Metabolic Disorders at Eastern Virginia Medical School, and lead investigator of the study. "These data suggest tapentadol ER provides a significant reduction in chronic pain in adult
'/>"/>

SOURCE Janssen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update
2. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
3. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
4. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
5. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
6. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
7. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
10. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
11. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014  CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced an ... lead drug candidate, aldoxorubicin.  The presentation, titled, "Drug ... will be given by Sant P. Chawla ... Center and principal investigator of the Company,s ongoing ...
(Date:10/30/2014)... -- , La fórmula de leche ... tolerancia a la proteína de leche de vaca  ... leche de la vaca (APLV) es la principal alergia alimentaria ... APLV se trataba eliminando las proteínas lácteas de ... posible adquirir tolerancia oral en un número significativo ...
(Date:10/30/2014)... Oct. 30, 2014  TWi Pharmaceuticals, Inc. today announced ... States Food and Drug Administration (FDA) on its Abbreviated ... 23 mg, the generic equivalent to Eisai Inc.,s Aricept® ... patients. TWi Pharmaceuticals is preparing to launch ... subsidiary, TWi Pharmaceuticals USA , at ...
Breaking Medicine Technology:CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3
... 28, 2011 Nile Therapeutics, Inc. (Nasdaq: ... novel therapeutics for heart failure patients, today announced plans ... ) on the clinical development of Nile,s proprietary natriuretic ... disease applications. "We are very pleased to ...
... Feb. 28, 2011 PAREXEL International Corporation (Nasdaq: ... presenting at the Raymond James Investors Conference in Orlando, FL. ... be making a presentation on PAREXEL at 2:50 p.m.  ET ... of this presentation will be available through the "Investors" ...
Cached Medicine Technology:Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 2Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 3PAREXEL International to Present at Raymond James Investors Conference 2
(Date:10/28/2014)... and outer body and organ surfaces in the human ... in the inner ear," said Moritz Gegg. Cilia – ... are precisely positioned on many of these epithelial cells. ... coordinated so precisely that for example mucus can be ... from sensory inner ear hair cells," added Heiko Lickert. ...
(Date:10/27/2014)... discarding microscopic warning signs about your health. , But a ... "going to waste." , Brigham Young University chemist Adam Woolley ... of kidney disease and prostate cancer in a few minutes. ... a tiny tube and see how far it goes. , ... will latch onto disease markers and nothing else. Urine from ...
(Date:10/27/2014)... a new therapy by watching others use it, Surprisingly ... New technology is like an influential colleague -- opinionated ... every five to seven days , CHICAGO --- ... they are persuaded to do so by an influential colleague, ... innovations also have relevance for business, education and research. ...
(Date:10/27/2014)... 27, 2014 Jiwa Law Corporation now ... are involved in motor vehicle accidents. The corporation now ... and rehabilitation expenses up to a maximum of $150,000. ... or chiropractor treatments, medications, home support services, and medical ... huge impact on the way you live your life,” ...
(Date:10/27/2014)... -- For children with broken bones, ibuprofen is ... researchers report. Although both medications are ... injuries, oral morphine carries more risk for negative ... that orally administered morphine and other [narcotic painkillers] ... evidence for the oral administration of morphine in ...
Breaking Medicine News(10 mins):Health News:New insights into the development of ciliopathies 2Health News:Prostate cancer, kidney disease detected in urine samples on the spot 2Health News:Persuading doctors to quickly adopt new treatments 2Health News:Persuading doctors to quickly adopt new treatments 3Health News:Jiwa Law Corporation Now Assists Clients With ICBC Claims for Motor Vehicle Accidents 2Health News:For a Child's Fracture, Use Ibuprofen, Not Morphine: Study 2
... problem often leading to diabetes and cardiovascular disease. Being ... // resistant, but not all overweight or obese people ... insulin resistance, however, it is too difficult to administer ... have come up with a simple way to identify ...
... new study was conducted by the Johns Hopkins Bloomberg School ... 55 and older. Researchers used magnetic resonance imaging// to determine ... changes in the brain correlated with the risk of stroke ... moderate alcohol consumption and a decrease in brain size of ...
... surgery, according to a new study done by researchers ... //results are due to medical or psychosocial factors. ... surgery than men. Most have attributed this to the fact ... and have fewer social supports. In this study, investigators from ...
... drugs that lower cholesterol levels, research shows they remain ... a patient is in the hospital or at a ... Foundation looked at the relationship between when lipid-lowering therapy ... outpatient setting and its long-term use. ,For the ...
... major complication of diabetes, despite the fact most are ... performed among the diabetic population. ,Researchers studied ... of about 900 diabetic patients who had been diagnosed ... for 20 years to assess how these microvascular changes ...
... may improve strength and mobility in patients with osteoarthritis.// ... osteoarthritis who were older than age 50. Patients were divided ... week in a swimming pool, the second exercised in a ... the water and gym programs focused on resistance exercises. ...
Cached Medicine News:
Solid lower plate with outside width 15 mm. Open serrated upper plate with inside dimensions 9 x 12 mm. Serrated handle with locking thumb screw and polished finish....
Oval solid 15 mm wide lower plate. Open upper plate with inside dimensions 11 mm x 8 mm. Serrated handle with locking thumb screw and polished finish....
1 mm smooth 45 degrees angled jaws. Cross action serrated handle with polished finish....
Solid lower plate with outside width 28 mm. Open upper plate. Serrated handle with locking thumb screw and polished finish. Right....
Medicine Products: